An international multisite research collaboration, including CITF-funded researcher Dr. Andrés Finzi from the Université de Montréal, used genetically modified mice that mimic COVID-19 disease in humans to study how antibodies from people who have recovered from COVID-19 could prevent severe disease in other people. The authors concluded that these antibodies were effective in not only blocking SARS-CoV-2 infection, but also in allowing mice infected with a lethal dose of the virus to fully recover. This work, recently released as a pre-print and therefore not peer-reviewed, was partially funded by the COVID-19 Immunity Task Force.
For this study, mice were infected with SARS-CoV-2 virus expressing a bioluminescent reporter, making it possible to visualize the infected tissues in the live animals. The use of this small animal model allows scientists to answer questions that otherwise would go unanswered as human test subjects cannot be used. They used a technique called live bioluminescence imaging (BLI), which allowed the team to take pictures inside the mice to identify which tissues were infected, over time. Mice that were genetically modified to express the human receptor for SARS-CoV-2 in all their cells were used, meaning they could be infected in similar ways to humans.
Researchers then injected some of the mice with neutralizing antibodiesAntibodies that bind to the surface structures of a pathogen, preventing it from entering and infecting its host cells. (antibodies from a donor who have recovered from COVID-19 from the team’s CR-CHUM cohort) and compared the results to mice not given any treatment. In mice who received no antibodies, SARS-CoV-2 spread from the nasal cavity (the infection point) to the lungs, followed by a systemic spread to various organs including the brain, and subsequently culminating in death. The authors demonstrated that mice that were administered neutralizing antibodies before being injected with SARS-CoV-2 were resistant to infection. In another experiment, they administered antibody treatments after infection to determine how they acted. The treatment with neutralizing antibodies also cleared the virus from established infections when administered within the first three days post-infection (See Figure 1).
Finally, the authors evaluated the mechanisms involved in the potent antiviral effect of the neutralizing antibodies. They concluded that these antibodies did more than simply neutralize SARS-CoV-2. They demonstrated in detail in their paper, that for these antibodies to fully exert their protective capacity, they need to be able to interact with several types of immune cells including monocytes, neutrophils, and natural killer cells (a mechanism known as Fc-mediated effector functions). This interaction was needed to dampen the general inflammatory responses that can actually make the disease worse. The authors proposed that their small animal model can be used to identify effective antiviral therapies that can be rapidly extrapolated for clinical use in humans.
Irfan Ullah, Jérémie Prévost, Mark S Ladinsky, Helen Stone, Maolin Lu, Sai Priya Anand, Guillaume Beaudoin-Bussières, Mehdi Benlarbi, Shilei Ding, Romain Gasser, Corby Fink, Yaozong Chen, Alexandra Tauzin, Guillaume Goyette, Catherine Bourassa, Halima Medjahed, Matthias Mack, Kunho Chung, Craig B Wilen, Gregory A. Dekaban, Jimmy D. Dikeakos, Emily A. Bruce, Daniel E Kaufmann, Leonidas Stamatatos, Andrew T. McGuire, Jonathan Richard, Marzena Pazgier, Pamela J. Bjorkman, Walther Mothes, Andrés Finzi, Priti Kumar, Pradeep D. Uchil. Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy. bioRxiv 2021.03.22.436337; Posted March 22, 2021. doi: https://doi.org/10.1101/2021.03.22.436337